BioLineRx Ltd. (BLRX)

0.6565 +0.0164 (+2.56%) At close: 04:00PM EDT

BioLineRx Ltd.

Modi’in Technology Park
2 HaMa’ayan Street
Hevel Modi'in 7177871
Israel
972 8 642 9100
https://www.biolinerx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 79

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA	Chief Executive Officer	598k	N/A	1960
Ms. Mali Zeevi CPA, CPA	Chief Financial Officer	374k	N/A	1976
Dr. Ella Sorani Ph.D.	Chief Development Officer	452k	N/A	1968
Ms. Holly W. May M.B.A.	President of BioLineRx USA	710k	N/A	1962
Mr. John Lacey	Head of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.	Head of BD & Strategic Advisor	N/A	N/A	N/A
Mr. Raziel Fried	Treasurer & Budgetary Control Director	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

Corporate Governance

BioLineRx Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.